Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070692 · ClinicalTrials.gov registry record · Phase 4
Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
A Phase 4 study of Menstruation Disturbances, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT02070692 is a Phase 4 study of Menstruation Disturbances that has completed, run by Oregon Health and Science University. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02070692, a Phase 4 study of Menstruation Disturbances, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tamoxifen
Study Locations (1)
Oregon
- Oregon Health & Science University (OHSU) - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070692
The ClinicalTrials.gov registry entry for NCT02070692 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Menstruation Disturbances appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02070692 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02070692 about?
NCT02070692 is a clinical study titled "Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users". The purpose of this study is to study whether a drug called tamoxifen can reduce vaginal bleeding in women who are using the Etonogestrel contraceptive implant.
What is the current status of trial NCT02070692?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2014-02. Estimated completion is 2015-12.
What conditions does trial NCT02070692 study?
This clinical trial studies the following conditions: Menstruation Disturbances.
What interventions are being tested in trial NCT02070692?
The interventions under investigation include: Placebo (DRUG), Tamoxifen (DRUG).
Who is sponsoring clinical trial NCT02070692?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02070692 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menstruation Disturbances
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.